(Q83540853)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Drug-induced PML: a global agenda for a global challenge (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

M Vinhas de Souza

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

B Keller-Stanislawski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

K Blake

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

A Hidalgo-Simon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

P Arlett

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

G Dal Pan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

29 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

747-750

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY.

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Monoclonal antibodies and progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Pharmacotherapeutic options for the management of human polyomaviruses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.4

7 January 2021

Identifiers

DOI

10.1038/CLPT.2012.4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22378158%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference